Treosulfan-Based Myeloablative Conditioning Enables Donor-Specific Tolerance and Stable Mixed Chimerism in Allogeneic Transplantation
Key Insights
Treosulfan, a bifunctional alkylating agent, demonstrates potent myeloablative activity while preserving the capacity to induce donor-specific transplantation tolerance across full MHC barriers.
A conditioning regimen combining treosulfan with anti-CD3 (search) monoclonal antibody and donor bone marrow transplantation achieves stable mixed chimerism and permanent skin allograft acceptance.
The protocol avoids the severe toxicity associated with traditional total body irradiation, offering a clinically translatable alternative for organ transplantation tolerance induction.
Researchers have demonstrated that treosulfan, a bifunctional alkylating agent with established antitumor activity, can serve as an effective myeloablative conditioning agent that enables the induction of donor-specific transplantation tolerance when combined with bone marrow transplantation. The findings, emerging from preclinical murine models, highlight a clinically promising alternative to traditional irradiation-based conditioning regimens that have limited translational applicability due to toxicity concerns.
The study builds upon decades of research into mixed chimerism as a strategy for achieving permanent transplantation tolerance without the need for lifelong immunosuppression. As noted in the literature, mixed chimerism—the coexistence of both donor and recipient hematopoietic cells—has been shown to induce "permanent specific transplantation tolerance induced by a nonlethal preparative regimen," a concept pioneered by Sharabi and Sachs in 1989.
Treosulfan's Dual Mechanism: Myeloablation and Tolerogenesis
Treosulfan functions through DNA alkylation and interstrand cross-linking, mechanisms that underpin both its antitumor efficacy and its capacity for hematopoietic stem cell depletion. Hartley and colleagues characterized this activity, demonstrating that treosulfan's "DNA alkylation and interstrand cross-linking" properties make it a potent cytotoxic agent. Westerhof and collaborators further established that treosulfan effectively depletes "murine bone marrow hematopoietic progenitors" both in vivo and in vitro, while comparative analyses confirmed its superiority over other busulfan analogues "for depletion of hematopoietic stem cells and promotion of donor-type chimerism in murine bone marrow transplant recipients."
The tolerogenic protocol employs a combination of treosulfan conditioning, a short course of anti-CD3 (search) monoclonal antibody, and transplantation of donor bone marrow cells. This approach draws on earlier work showing that "anti-CD3 treatment facilitates engraftment of full H-2-disparate donor bone marrow cells and subsequent skin allograft tolerance," as demonstrated by de Vries-van der Zwan and colleagues in 1994.
Clinical Implications and Antitumor Spectrum
Treosulfan's clinical profile extends well beyond conditioning. Phase I dose-escalation studies by Scheulen and colleagues evaluated "high-dose chemotherapy with treosulfan and autologous peripheral blood stem cell transplantation in patients with advanced malignancies," establishing pharmacokinetic parameters for clinical use. The agent has demonstrated activity against human lung carcinomas, breast carcinomas, malignant melanoma, and ovarian cancer (search), where it has been employed as "an effective second-line therapy." Fichtner and colleagues further documented "antileukaemic activity of treosulfan in xenografted human acute lymphoblastic leukemias (ALL)."
A clinical evaluation by Beelen assessed the "safety, efficacy and pharmacokinetics of dose-escalated treosulfan/cyclophosphamide conditioning prior to allogeneic transplantation of high-risk leukemia patients," underscoring the translational trajectory of this approach.
Regulatory T Cells and Tolerance Maintenance
The maintenance of transplantation tolerance induced through mixed chimerism relies heavily on regulatory T cell populations. CD4 (search)+CD25 (search)+ regulatory T cells have been shown to be "required for induction of tolerance to alloantigen via costimulatory blockade," and donor-type CD4+CD25+ regulatory T cells can "suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation." The interplay between treosulfan-mediated myeloablation and the subsequent reconstitution of regulatory T cell compartments represents a critical axis in achieving durable, donor-specific tolerance.
The protocol's ability to induce "specific skin graft acceptance across full MHC barriers" through hematopoietic stem cell transplantation, as previously demonstrated by de Vries-van der Zwan and colleagues, positions treosulfan-based conditioning as a promising platform for clinical translation in solid organ transplantation, potentially freeing recipients from the burden of chronic immunosuppression and its associated risks, including the well-documented increased incidence of malignancies in immunosuppressed transplant recipients.